吉西他滨联合顺铂或卡培他滨在发生耐药性的晚期乳腺癌临床治疗中的应用效果

Efficacy of gemcitabine combined with cisplatin or capecitabine in the treatment of advanced breast cancer with drug resistance

目的:探讨吉西他滨联合顺铂在发生耐药性的晚期乳腺癌临床治疗中的应用效果。方法:选择我院2015年12月～2017年12月收治的60例发生耐药性晚期乳腺癌患者为研究对象。采用随机数表法分为对照组和观察组,各30例。观察组采用GP方案,吉西他滨1000mg/m^2,于第1、8天给药,每次滴注时间为30min;顺铂25mg/m^2,于第1、2、3天给药,3周为1个治疗周期;对照组采用GC方案,吉西他滨用法同观察组,卡培他滨给药剂量1000mg/m^2,口服,2次/d,连续服用2周,3周为1个治疗周期。比较两组不良反应发生情况及临床疗效。结果:观察组恶心呕吐、手足综合征发生率明显低于对照组(P<0.05);两组其他不良反应发生率、化疗周期、进展时间、CR+PR,CR+PR+SD比较差异均无统计学意义(P>0.05)。结论:吉西他滨联合顺铂在发生耐药性的晚期乳腺癌治疗中应用的不良反应相对较低,临床治疗效果较好,值得推广。

Objective:to evaluate the efficacy of gemcitabine combined with cisplatin in the treatment of advanced breast cancer. Methods60 patients with advanced breast cancer with drug resistance were selected from December 2015 to December 2017. The patients were divided into control group(30 cases) and observation group(30 cases). The observation group was treated with GP regimen,gemcitabine 1000 mg/m^2,on the 1 st day 8 days for 30 min,cisplatin 25 mg/m^2 for 3 weeks,and the control group for 3 weeks. The control group was treated with cisplatin 25 mg/m^2 for 3 weeks. The control group was treated with gemcitabine for 3 weeks. The control group was treated with cisplatin 25 mg/m^2 for 3 weeks. The results showed that the incidence of nausea and vomiting and hand-foot syndrome in the observation group were significantly lower than those in the control group(P<0.05).There was no significant difference in the incidence of other adverse reactions,chemotherapy cycle,time of progression,CR+PR,CR+PR+SD(P >0.05). To lower,clinical treatment effect is better,it is worth further popularizing application.